Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sclerosing Cholangitis Clear all
Completed Phase 1 Interventional

Evaluation of DHA for the Treatment of PSC

NCT00325013
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Colitis
Interventions
Docosahexaenoic Acid (DHA)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

NCT02424175
View directory record Official record
Conditions
Sclerosing Cholangitis
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 26, 2026, 9:51 PM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting Phase 2 Interventional

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

NCT05295680
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Hymecromone
Drug
Lead sponsor
Aparna Goel
Other
Eligibility
14 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 26, 2026, 9:51 PM EDT
Completed No phase listed Observational

Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis

NCT00587236
View directory record Official record
Conditions
Colitis, Ulcerative, Cholangitis, Sclerosing
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

NCT04753996
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2035
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of Fenofibrate for PSC

NCT01142323
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
fenofibrate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting No phase listed Observational

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

NCT05750498
View directory record Official record
Conditions
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
No interventions
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
8
States / cities
Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Terminated Phase 2 Interventional Results available

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

NCT03394781
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
DUR-928
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

NCT05912387
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions
Rosuvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting No phase listed Observational

Primary Sclerosing Cholangitis in Children

NCT04181138
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
2 Years to 25 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Xifaxan to Treat Patients With PSC

NCT01695174
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Xifaxan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

CM-101 in PSC Patients -The SPRING Study

NCT04595825
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
Biological · Other
Lead sponsor
ChemomAb Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
La Jolla, California • Sacramento, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting Early Phase 1 Interventional

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

NCT06197308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
oral vancomycin and oral amoxicillin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 76 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

NCT00955149
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
Interventions
Erlotinib (Tarceva)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 26, 2026, 9:51 PM EDT
Not listed Phase 2 Interventional

Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

NCT01688024
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Mitomycin C, Normal saline
Drug
Lead sponsor
Li, Zhiping, M.D.
Individual
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 26, 2026, 9:51 PM EDT
Recruiting No phase listed Observational

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

NCT03178630
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Tuscon, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

NCT05525520
View directory record Official record
Conditions
Pruritus
Interventions
EP547, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 26, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis

NCT00004842
View directory record Official record
Conditions
Cholangitis, Sclerosing, Liver Cirrhosis, Biliary
Interventions
budesonide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 26, 2026, 9:51 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 26, 2026, 9:51 PM EDT
Terminated Phase 3 Interventional Results available

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

NCT03890120
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
82
States / cities
Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 26, 2026, 9:51 PM EDT
Terminated Phase 2 Interventional Results available

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

NCT00953615
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Thalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 26, 2026, 9:51 PM EDT